title: Complications from pharmacotherapy.
abstract: The pharmacotherapy management of cancers of the nervous system has significant overlap with systemic solid cancers that may utilize similar drugs or agents. There is however a unique aspect related to central nervous system (CNS) cancers where therapies directed against a malignant process may have enhanced toxicities or toxicities unique to the CNS. In addition, many agents used to treat CNS malignancies have unique CNS toxicities that may require a specific intervention. This chapter attempts to review conventional and biologic therapies utilized for CNS malignancies and characterize expected and, if known, unique toxicities.
authors.affiliation: Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: bnabors@uabmc.edu.
authors.forename: L Burt
authors.initials: LB
authors.lastname: Nabors
authors.affiliation: Department of Neurology, Kaiser-Franz-Josef Hospital, Vienna, Austria.
authors.forename: Birgit
authors.initials: B
authors.lastname: Surboeck
authors.affiliation: Department of Neurology, Kaiser-Franz-Josef Hospital, Vienna, Austria; Medical University of Vienna, Vienna, Austria.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Grisold
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents
keywords: adverse events; biologic therapies; chemotherapy; toxicity